Datapoint: FDA Approves Pfizer’s New Migraine Nasal Spray

The FDA on March 10 approved Pfizer Inc.’s Zavzpret for the treatment of acute migraine with or without aura in adult patients. While the drug is not the first migraine nasal spray on the market, it is the first calcitonin gene-related peptide (CGRP) receptor antagonist in that format, boasting a mechanism of action that can provide pain relief in as little as 15 minutes, according to phase 3 study data. Zavzpret enters a competitive market basket, which includes Impel Pharmaceuticals’ nasal spray Trudhesa. Impel in November said the drug has generated about 50,000 prescriptions since its commercial launch in October 2021. For the treatment of acute migraine, Trudhesa currently holds covered or better status for 59% of all insured lives under the pharmacy benefit. Coverage typically requires prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of  3/15/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 12

Datapoint: Centene to Expand Cityblock Partnership to Florida

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 11

Datapoint: SCAN Wins Stars Challenge Against CMS

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 10

Datapoint: Blue Cross and Blue Shield of Kansas City to Exit MA Market

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today